malignant otitis externa caused by Pseudomonas aeruginosa

Summary

malignant otitis externa caused by Pseudomonas aeruginosa (MONDO:0041095) is a disease. A subtype of malignant otitis externa — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant otitis externa caused by Pseudomonas aeruginosa
Mondo ID	MONDO:0041095
SNOMED CT	232230009
UMLS	C0395818
MedGen	583067
Is cancer (heuristic)	no

Also known as: malignant otitis externa caused by Pseudomonas aeruginosa · malignant otitis externa due to Pseudomonas aeruginosa · Pseudomonas aeruginosa caused malignant otitis externa · Pseudomonas aeruginosa malignant otitis externa

Disease family

This is a subtype of malignant otitis externa. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › external ear disorder › otitis externa › malignant otitis externa › malignant otitis externa caused by Pseudomonas aeruginosa

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.